Xiaohong Wu
Jiangnan University(CN)Fujian Medical University(CN)Target (United States)(US)Harbin Medical University(CN)China National Nuclear Corporation(CN)Huaibei Normal University(CN)Chengdu Medical College(CN)Sir Run Run Shaw Hospital(CN)Yale University(US)Theranostics (New Zealand)(NZ)Wuxi Fourth People's Hospital(CN)Zhejiang Provincial People's Hospital(CN)Chengdu Second People's Hospital(CN)Second Affiliated Hospital of Fujian Medical University(CN)National Institutes for Food and Drug Control(CN)Xiamen Chang Gung Hospital(CN)Huaiyin Institute of Technology(CN)Hangzhou Medical College(CN)Sichuan Center for Disease Control and Prevention(CN)Zhejiang University(CN)
Publications by Year
Research Areas
Pancreatic function and diabetes, Immunotherapy and Immune Responses, SARS-CoV-2 and COVID-19 Research, Thyroid Cancer Diagnosis and Treatment, Lung Cancer Treatments and Mutations
Most-Cited Works
- → Advances in COVID-19 mRNA vaccine development(2022)570 cited
- → AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations(2022)261 cited
- → The Dual Functions of WLIM1a in Cell Elongation and Secondary Wall Formation in Developing Cotton Fibers(2013)230 cited
- → Early wheat in China: Results from new studies at Donghuishan in the Hexi Corridor(2010)208 cited
- → Cardiac macrophage migration inhibitory factor inhibits JNK pathway activation and injury during ischemia/reperfusion(2009)173 cited
- → Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)(2022)164 cited